BIOM 3090 Lecture Notes - Lecture 8: Phenylephrine, Insomnia, Salbutamol

• School: University of Guelph
• Department: Biomedical Sciences
• Course: BIOM 3090
• Professor: Bettina Kalisch

Document Summary

Table 1 showing the cholinergic agonist drug list. Widespread action of ach makes it difficult to obtain selective effects as many cholinergic agents are capable of both stimulating and blocking cholinergic receptors. Based on this, non- selective muscarinic receptor agonists are not widely used and subtype selective agonists are currently not used clinically. Furthermore, no nn or nm nicotinic receptor subtype selective agonists used to treat disorders. Systemic receptor activation by direct-acting muscarinic and nicotinic agonists would produce desired therapeutic effects but also undesirable side-effects. For nicotinic agonists, receptor binding activates psns and sns branches of the autonomic nervous system and causes skeletal muscle contraction and stimulates nicotinic receptors in the brain. Sns heart eye, salivary gland, lacrimal glands , bronchi, stomach, small intestine, colon, sweat glands genitals, bladder. Most of the tissue effe(cid:272)ts a(cid:396)e (cid:373)ediated (cid:271)(cid:455) m(cid:1006) a(cid:374)d m(cid:1007) (cid:396)e(cid:272)epto(cid:396)s. pa(cid:396)as(cid:455)(cid:373)patheti(cid:272) (cid:374)e(cid:396)(cid:448)es do(cid:374)"t innervate blood vessels but m3 receptors are present on endothelial cells that line blood vessels.